Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K on July 30, 2026, to report its financial results for the second quarter of 2026. The filing includes a press release detailing the financial performance and a presentation outlining key financial and operating initiatives. Investors should note that both furnished documents reference non-GAAP financial information, with reconciliations and explanations available in the press release. While the specific financial figures are not detailed within this 8-K's text, the report serves as the official announcement mechanism for BMY's Q2 2026 performance. The company has made these materials available on its website, emphasizing the importance of the accompanying press release and presentation for understanding the company's financial health and strategic direction.
Key Highlights
- 1BMY announced its second quarter 2026 financial results via an 8-K filing on July 30, 2026.
- 2The filing includes a press release (Exhibit 99.1) with detailed Q2 2026 financial results.
- 3A presentation (Exhibit 99.2) on financial and operating initiatives is also furnished.
- 4Both the press release and presentation contain non-GAAP financial measures.
- 5Reconciliations and explanations for non-GAAP measures are provided in the press release.
- 6The information furnished is not considered 'filed' for Section 18 purposes, but is important for understanding Q2 performance.
- 7Materials are available on the company's website (www.bms.com).